A Study to Investigate the Safety and Tolerability of Oral INR731 Single Agent or in Combination With Androgen Receptor Pathway Inhibitor (ARPI) in Patients With Metastatic Prostate Cancer

NCT07570979 · clinicaltrials.gov ↗

PHASE1

Phase

RECRUITING

Status

208

Enrollment

INDUSTRY

Sponsor class

Conditions

Metastatic Castration-resistant Prostate Cancer (mCRPC)

Interventions

DRUG: INR731
DRUG: Enzalutamide
DRUG: Abiraterone
DRUG: Androgen deprivation therapy (ADT)

Sponsor

Novartis Pharmaceuticals